Clinical Trials

Retrospective part (closed to patients registration):

• Men with histologically proven invasive breast carcinoma diagnosed since 1990 to 2010.
• A FFPE tissue sample from the primary tumor (e.g. biopsy or surgery) is mandatory

Prospective part:

• All men, with histologically proven invasive breast cancer, newly presenting at the center irrespective of the stage of disease, initial diagnosis date or treatment received
  • patients cannot be registered in both the retrospective and prospective parts of the study
  • patients who newly present at the center in the 3 months prior to center activation are still eligible as long as they were not previously included in the retrospective part of the study
• Before patient registration, written informed consent must be obtained according to ICH/GCP, and national/local regulations.
• Collection of left-over FFPE and frozen tumor samples as well as blood is optional.

Both parts:

• Concomitant DCIS or LCIS are allowed only if invasive cancer is present.
• Patients should be 18 years or over at the time of diagnosis.
• The study will accept all stages of disease (e.g. early BC, locally advanced and metastatic disease) independent of the treatment received.
• Patients with past or concurrent other malignancies are eligible.